Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells

Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Ravindra Kolhe, Aditya Mandawat, Yongchao Wang, Rajeshree Joshi, Kelly Eaton, Pearl Lee, Peter Atadja, Stephen Peiper, Kapil Bhalla

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Hydroxamic acid analog pan-histone deacetylase (HDAC) inhibitors (HA-HDIs) have shown preclinical and clinical activity against human acute leukemia. Here we describe HA-HDI-resistant human acute myeloid leukemia (AML) HL-60 (HL-60/LR) cells that are resistant to LAQ824, vorinostat, LBH589, and sodium butyrate. HL-60/LR cells show increased expression of HDACs 1, 2, and 4 but lack HDAC6 expression, with concomitant hyperacetylation of heat shock protein 90 (hsp90). Treatment with HA-HDI failed to further augment hsp90 acetylation, or increase the levels of p21 or reactive oxygen species (ROSs), in HL-60/LR versus HL-60 cells. Although cross-resistant to antileukemia agents (eg, cytarabine, etoposide, and TRAIL), HL-60/LR cells are collaterally sensitive to the hsp90 inhibitor 17-AAG. Treatment with 17-AAG did not induce hsp70 or deplete the hsp90 client proteins AKT and c-Raf. HL-60/LR versus HL-60 cells display a higher growth fraction and shorter doubling time, along with a shorter interval to generation of leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Thus, resistance of AML cells to HA-HDIs is associated with loss of HDAC6, hyperacetylation of hsp90, aggressive leukemia phenotype, and collateral sensitivity to 17-AAG. These findings suggest that an hsp90 inhibitor-based antileukemia therapy may override de novo or acquired resistance of AML cells to HA-HDIs.

Original languageEnglish (US)
Pages (from-to)2896-2905
Number of pages10
JournalBlood
Volume112
Issue number7
DOIs
StatePublished - Oct 1 2008

Fingerprint

HSP90 Heat-Shock Proteins
Histone Deacetylase Inhibitors
Hydroxamic Acids
Myeloid Cells
tanespimycin
Acute Myeloid Leukemia
Histone Deacetylases
HL-60 Cells
Pharmaceutical Preparations
Leukemia
Acetylation
Butyric Acid
Cytarabine
Etoposide
Reactive Oxygen Species
SCID Mice
Human Activities
Phenotype
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells. / Fiskus, Warren; Rao, Rekha; Fernandez, Pravina; Herger, Bryan; Yang, Yonghua; Chen, Jianguang; Kolhe, Ravindra; Mandawat, Aditya; Wang, Yongchao; Joshi, Rajeshree; Eaton, Kelly; Lee, Pearl; Atadja, Peter; Peiper, Stephen; Bhalla, Kapil.

In: Blood, Vol. 112, No. 7, 01.10.2008, p. 2896-2905.

Research output: Contribution to journalArticle

Fiskus, W, Rao, R, Fernandez, P, Herger, B, Yang, Y, Chen, J, Kolhe, R, Mandawat, A, Wang, Y, Joshi, R, Eaton, K, Lee, P, Atadja, P, Peiper, S & Bhalla, K 2008, 'Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells', Blood, vol. 112, no. 7, pp. 2896-2905. https://doi.org/10.1182/blood-2007-10-116319
Fiskus, Warren ; Rao, Rekha ; Fernandez, Pravina ; Herger, Bryan ; Yang, Yonghua ; Chen, Jianguang ; Kolhe, Ravindra ; Mandawat, Aditya ; Wang, Yongchao ; Joshi, Rajeshree ; Eaton, Kelly ; Lee, Pearl ; Atadja, Peter ; Peiper, Stephen ; Bhalla, Kapil. / Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells. In: Blood. 2008 ; Vol. 112, No. 7. pp. 2896-2905.
@article{7205d1e246be412da33fe7dca7539dbe,
title = "Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells",
abstract = "Hydroxamic acid analog pan-histone deacetylase (HDAC) inhibitors (HA-HDIs) have shown preclinical and clinical activity against human acute leukemia. Here we describe HA-HDI-resistant human acute myeloid leukemia (AML) HL-60 (HL-60/LR) cells that are resistant to LAQ824, vorinostat, LBH589, and sodium butyrate. HL-60/LR cells show increased expression of HDACs 1, 2, and 4 but lack HDAC6 expression, with concomitant hyperacetylation of heat shock protein 90 (hsp90). Treatment with HA-HDI failed to further augment hsp90 acetylation, or increase the levels of p21 or reactive oxygen species (ROSs), in HL-60/LR versus HL-60 cells. Although cross-resistant to antileukemia agents (eg, cytarabine, etoposide, and TRAIL), HL-60/LR cells are collaterally sensitive to the hsp90 inhibitor 17-AAG. Treatment with 17-AAG did not induce hsp70 or deplete the hsp90 client proteins AKT and c-Raf. HL-60/LR versus HL-60 cells display a higher growth fraction and shorter doubling time, along with a shorter interval to generation of leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Thus, resistance of AML cells to HA-HDIs is associated with loss of HDAC6, hyperacetylation of hsp90, aggressive leukemia phenotype, and collateral sensitivity to 17-AAG. These findings suggest that an hsp90 inhibitor-based antileukemia therapy may override de novo or acquired resistance of AML cells to HA-HDIs.",
author = "Warren Fiskus and Rekha Rao and Pravina Fernandez and Bryan Herger and Yonghua Yang and Jianguang Chen and Ravindra Kolhe and Aditya Mandawat and Yongchao Wang and Rajeshree Joshi and Kelly Eaton and Pearl Lee and Peter Atadja and Stephen Peiper and Kapil Bhalla",
year = "2008",
month = "10",
day = "1",
doi = "10.1182/blood-2007-10-116319",
language = "English (US)",
volume = "112",
pages = "2896--2905",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells

AU - Fiskus, Warren

AU - Rao, Rekha

AU - Fernandez, Pravina

AU - Herger, Bryan

AU - Yang, Yonghua

AU - Chen, Jianguang

AU - Kolhe, Ravindra

AU - Mandawat, Aditya

AU - Wang, Yongchao

AU - Joshi, Rajeshree

AU - Eaton, Kelly

AU - Lee, Pearl

AU - Atadja, Peter

AU - Peiper, Stephen

AU - Bhalla, Kapil

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Hydroxamic acid analog pan-histone deacetylase (HDAC) inhibitors (HA-HDIs) have shown preclinical and clinical activity against human acute leukemia. Here we describe HA-HDI-resistant human acute myeloid leukemia (AML) HL-60 (HL-60/LR) cells that are resistant to LAQ824, vorinostat, LBH589, and sodium butyrate. HL-60/LR cells show increased expression of HDACs 1, 2, and 4 but lack HDAC6 expression, with concomitant hyperacetylation of heat shock protein 90 (hsp90). Treatment with HA-HDI failed to further augment hsp90 acetylation, or increase the levels of p21 or reactive oxygen species (ROSs), in HL-60/LR versus HL-60 cells. Although cross-resistant to antileukemia agents (eg, cytarabine, etoposide, and TRAIL), HL-60/LR cells are collaterally sensitive to the hsp90 inhibitor 17-AAG. Treatment with 17-AAG did not induce hsp70 or deplete the hsp90 client proteins AKT and c-Raf. HL-60/LR versus HL-60 cells display a higher growth fraction and shorter doubling time, along with a shorter interval to generation of leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Thus, resistance of AML cells to HA-HDIs is associated with loss of HDAC6, hyperacetylation of hsp90, aggressive leukemia phenotype, and collateral sensitivity to 17-AAG. These findings suggest that an hsp90 inhibitor-based antileukemia therapy may override de novo or acquired resistance of AML cells to HA-HDIs.

AB - Hydroxamic acid analog pan-histone deacetylase (HDAC) inhibitors (HA-HDIs) have shown preclinical and clinical activity against human acute leukemia. Here we describe HA-HDI-resistant human acute myeloid leukemia (AML) HL-60 (HL-60/LR) cells that are resistant to LAQ824, vorinostat, LBH589, and sodium butyrate. HL-60/LR cells show increased expression of HDACs 1, 2, and 4 but lack HDAC6 expression, with concomitant hyperacetylation of heat shock protein 90 (hsp90). Treatment with HA-HDI failed to further augment hsp90 acetylation, or increase the levels of p21 or reactive oxygen species (ROSs), in HL-60/LR versus HL-60 cells. Although cross-resistant to antileukemia agents (eg, cytarabine, etoposide, and TRAIL), HL-60/LR cells are collaterally sensitive to the hsp90 inhibitor 17-AAG. Treatment with 17-AAG did not induce hsp70 or deplete the hsp90 client proteins AKT and c-Raf. HL-60/LR versus HL-60 cells display a higher growth fraction and shorter doubling time, along with a shorter interval to generation of leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Thus, resistance of AML cells to HA-HDIs is associated with loss of HDAC6, hyperacetylation of hsp90, aggressive leukemia phenotype, and collateral sensitivity to 17-AAG. These findings suggest that an hsp90 inhibitor-based antileukemia therapy may override de novo or acquired resistance of AML cells to HA-HDIs.

UR - http://www.scopus.com/inward/record.url?scp=53449090857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449090857&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-10-116319

DO - 10.1182/blood-2007-10-116319

M3 - Article

VL - 112

SP - 2896

EP - 2905

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -